tiprankstipranks
ChromaDex Reports Strong Q3 2024 Financial Results
Company Announcements

ChromaDex Reports Strong Q3 2024 Financial Results

ChromaDex Corporation ( (CDXC) ) has released its Q3 earnings. Here is a breakdown of the information ChromaDex Corporation presented to its investors.

Don't Miss our Black Friday Offers:

ChromaDex Corporation is a global bioscience company that specializes in pioneering research on NAD+ and its role in cellular metabolism, offering products like Tru Niagen® to support healthy aging.

ChromaDex Corporation has reported an impressive performance for the third quarter of 2024, with a remarkable 31% increase in total net sales compared to the previous year, reaching $25.6 million. The company achieved a gross margin of 63.5% and a record net income of $1.9 million, highlighting strong financial health and strategic growth.

Key drivers of this growth include a significant rise in Niagen® ingredient sales, which soared by 368% year-over-year, and steady gains in Tru Niagen® sales. The company also improved its sales and marketing efficiency, reducing expenses as a percentage of net sales by 350 basis points. Additionally, ChromaDex celebrated its 25th anniversary by expanding the availability of its Niagen+ product line to over 100 wellness clinics, reflecting its commitment to innovative health solutions.

Looking forward, ChromaDex aims for approximately 15% revenue growth for the full year, focusing on expanding its e-commerce business and strategic partnerships. The company plans to maintain its investment in research and development to drive future innovation while keeping a stable expense structure to support brand awareness and market expansion.

Related Articles
TheFlyChromaDex price target raised to $8 from $6 at Roth MKM
TheFlyBiotech Alert: Searches spiking for these stocks today
TheFlyChromaDex price target raised to $8 from $6 at H.C. Wainwright
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App